Affiliation:
1. Vancouver Infectious Diseases Centre, Vancouver, BC V6Z2C7, Canada
Abstract
Advances in hepatitis C virus (HCV) treatment led to the development of highly effective all oral direct acting antiviral regimens. The combination of sofosbuvir and velpatasvir (SOF/VEL), two agents acting synergistically at different stages in the viral life cycle, has been evaluated in a broad range of clinical trials supporting its efficacy in complex and diverse patient populations. Following regulatory approval in 2016, SOF/VEL has been widely used as a safe, effective pangenotypic regimen in clinical practice. In this review, we will discuss the current preclinical, clinical and real-world data on SOF/VEL.
Reference63 articles.
1. WHO. Fact sheets: Hepatitis C (2019). www.who.int/news-room/fact-sheets/detail/hepatitis-c
2. WHO. Combating hepatitis B and C to reach elimination by 2030 (2016). www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/
3. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
4. WHO. News release: WHO urges countries to invest in eliminating hepatitis (2019). www.who.int/news-room/detail/26-07-2019-who-urges-countries-to-invest-in-eliminating-hepatitis
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献